Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Sony Invests Millions in Medical Devices and Clinical Pathology

By LabMedica International staff writers
Posted on 18 May 2012
The Israeli business daily Globes (Israel) reported that Sony Corporation (New York, NY, USA) is actively seeking to invest hundreds of millions of dollars in Israeli medical technologies. More...
The consumer electronics company wants to create patient-friendly medical devices and diagnostic kits that will be used in point-of-care settings.

Sony is preparing for a major expansion into the world of medical devices, with a particular interest in medical laboratory testing and diagnostic test kits. Experts regard Sony’s new strategy as a sign that prospects in diagnostic testing remain strong.

This is a major strategy change for Sony. Company officials state that Sony will rely less on consumer electronics as it shifts its focus to healthcare sectors, in an effort to revive earnings

Sony is interested in the attractive business prospects for moving into healthcare. “As populations age, demand for medical devices rises, and we intend to participate in this,” declared Hiroshi Yoshioka, vice president, Sony, Inc., in the Globes article. The Globes story serves to demonstrate how the boundaries between consumer electronics and medical devices are blurring.

Recently, Sony applied for a patent that would use a wristband to monitor the heart rate, vital signs, and blood glucose levels of the wearer. This information would be transmitted to a compatible HDTV where the user could see this data. This would be transmitted to medical personnel if necessary.

The techno Website Engadget posted a news story about how Sony is combining medical device functions with consumer electronics. Pathologists and clinical laboratory managers will find the functions of Sony's patent to be very relevant to their work.

Sony is the latest corporate giant to recognize that it can benefit from the confluence of the fields of biotechnology, medical devices, high tech electronics, information technology, and telecommunications. These various technologies are being combined to create “smart” medical devices, according to BioDFW (Dallas, TX, USA, a life sciences regional alliance.

Related Links:

Globes
Sony Corporation
BioDFW


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.